Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 17, 2008

Midatech Forms Nanotech-Focused Subsidiary

  • Midatech Group has formed a new drug development subsidiary, PharMida. Formation of this Basel-based unit follows an investment by a group of Switzerland-based private investors into Midatech. PharMida will be headed by Fritz R. Buhler, M.D., as chairman and Jan Mous, Ph.D., as CEO.

    The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage a collection of already existing and promising Midatech products or product lines.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »